DELRAY BEACH, Fla., June 4, 2025 /PRNewswire/ -- The global Coagulation Analyzer Market, valued at US$3,516.0 million in 2024 stood at US$3,770.9 million in 2025 and is projected to advance at a resilient CAGR of 7.2% from 2025 to 2030, culminating in a forecasted valuation of US$5,335.9 million by the end of the period. The market is experiencing steady growth, primarily driven by the increasing prevalence of blood clotting disorders such as hemophilia and deep vein thrombosis. As the global population ages and chronic illnesses become more common, the demand for quick and accurate diagnostic tools continues to rise.
Hospitals and laboratories are increasingly adopting automated analyzers to improve efficiency and reduce turnaround times. Additionally, the rise of point-of-care testing is significant, as it enables faster decision-making in critical care situations. Furthermore, the ongoing efforts to enhance healthcare infrastructure in emerging nations, along with the incorporation of technologies like artificial intelligence, are creating new opportunities for companies within this sector.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392
Browse in-depth TOC on "Coagulation Analyzer Market"
419 - Tables
45 - Figures
328 - Pages
By Based on product, The coagulation analyzers market is divided based on product type into clinical laboratory analyzers and point-of-care testing analyzers. In 2024, the clinical laboratory analyzers segment held the largest market share. This growth can be attributed to the increasing prevalence of conditions such as thrombosis and other bleeding disorders. Additionally, investments in healthcare infrastructure, particularly in emerging markets, along with the rise of both centralized and decentralized laboratories in developing countries, are driving greater investments in fully automated, high-throughput coagulation analyzers to accommodate large sample volumes. Clinical laboratory analyzers are further categorized into consumables and systems.
By Based on technology, The coagulation analyzers market is categorized into four segments based on technology: optical technology, mechanical technology, electrochemical technology, and other technologies. Among these, the electrochemical technology segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the faster measurement of clotting time achieved by electrochemical systems compared to optical or mechanical systems, which enhances clinical decision-making in time-critical situations such as trauma or surgery. Additionally, electrochemical devices typically require smaller blood samples and fewer reagents, leading to lower costs and enabling their use in critical care settings.
By geography, the coagulation analyzers market is divided into five major regional segments: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the Asia Pacific region accounted for the largest share of the coagulation analyzers market. Several factors are contributing to the growth of this market in Asia Pacific, including the rising incidence and prevalence of blood-related disorders, increasing government initiatives to improve healthcare infrastructure, a growing number of general surgeries, and enhanced research activities.
Additionally, the rapidly growing geriatric population is leading to an increase in conditions such as thalassemia, sickle-cell anemia, and leukemia. Countries like Japan, China, and Australia are experiencing improvements in their healthcare infrastructures, which are expected to further drive the demand for coagulation analyzers in the coming years.
According to a 2023 report from China's Ministry of Civil Affairs and the China National Committee on Ageing, the country's aging population is expanding rapidly. There are currently 216.76 million people aged 65 and older, accounting for 15.4% of the total population, and nearly 297 million individuals aged 60 and above, representing 21.1% of the population. Older adults are at higher risk for developing conditions like cardiovascular disease, deep vein thrombosis, and other coagulopathies, making regular coagulation testing essential for effective management.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197226392
Some of the prominent players operating in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Diagnostica Stago, Inc. (France), Werfen (Spain), Nihon Kohden Corporation (Japan), Helena Laboratories Corporation (US), Danaher (US), HORIBA, Ltd. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), among others.
Werfen (Spain):
Werfen is a global healthcare company focused on developing, producing, and distributing diagnostic products for clinical laboratories. The company has a strong presence in the coagulation analyzers market, supported by a focused strategy, a robust global footprint, and continuous innovation. In 2024, Werfen reported a 6% growth in revenue and improved operating income, driven by strong performances across all regions and core business segments, particularly in hemostasis. The company's leadership is bolstered by a dedicated team of approximately 1,800 professionals working in its Hemostasis and Acute Care technology centers, driving both innovation and product development. With over 13,081 ACL TOP systems (across all models) installed worldwide, Werfen has established a significant installed base, showcasing extensive clinical confidence and high customer acceptance.
Sysmex Corporation (Japan)
Sysmex Corporation has firmly established itself as a leader in the coagulation analyzers market, largely due to its ability to produce reagents on a massive scale across 14 locations worldwide. Additionally, the company collaborates with approximately 250 trusted top-tier suppliers, which helps ensure a smooth and efficient supply chain. Sysmex's Hemostasis segment has been consistently growing at around 4%, and the company is dedicated to meeting this demand by continuously innovating and upgrading its offerings. Its impressive investment of USD 630 million in research and development from 2021 to 2023 demonstrates its commitment to advancing technology and maintaining a competitive edge in the industry.
Diagnostic Stago, Inc. (France)
Diagnostic Stago, Inc. (France) boasts a diverse and specialized product range, a robust international distribution network, and a strong commitment to innovation in the field of coagulation. With over 350 coagulation products and an efficient commercial network of subsidiaries and distributors, Stago has established itself as the market leader in hemostasis diagnostics. The company's impressive manufacturing capability, producing more than 2,800 analyzers annually-including various coagulation systems-demonstrates its operational scale and viability. Notably, more than 750 coagulation tests are performed per minute on Stago systems worldwide, highlighting the widespread trust in and popularity of its technology. Furthermore, dedicating 20% of its workforce to research and development underscores Stago's strategic focus on continuous innovation, ensuring the company remains at the forefront of diagnostic advancements in coagulation testing.
Siemens Healthineers AG (Germany)
Siemens Healthineers AG (Germany) operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Diagnostics segment focuses on coagulation products. It sells its products to healthcare providers in over 180 countries. The company invests significantly in research and development (R&D) to introduce innovative and technologically advanced products. In 2024, it invested USD 2,107.7 million of its revenue in R&D activities. The company has major R&D facilities in Germany, the US, China, and India.
F. Hoffmann-La Roche Ltd. (Switzerland)
F. Hoffmann-La Roche Ltd. (Switzerland) offers a variety of coagulation analyzers, including the cobas t 711, renowned for their high throughput and seamless integration with advanced software, enhancing the efficiency of lab operations. With a global presence that spans North America, Europe, the Middle East, Africa, and Asia, Roche effectively serves a diverse range of customers. The company is committed to substantial investments in research and development; last year, R&D expenditures increased by 2% as it continued to focus on high-value medical assays, driving ongoing innovation in diagnostic technology, particularly in coagulation testing.
For more information, Inquire Now!
Related Reports:
Plasma Fractionation Market
Hematology Analyzers and Reagents Market
Point of Care Diagnostics Market
Clinical Chemistry Analyzers Market
In Vitro Diagnostics Market
Get access to the latest updates on Coagulation Analyzer Companies and Coagulation Analyzer Market Size
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/coagulation-analyzer-market-worth-us5-335-9-million-by-2030-with-7-2-cagr--marketsandmarkets-302472901.html
